Location History:
- Umea, SE (2009)
- Umeå, SE (2018)
Company Filing History:
Years Active: 2009-2018
Title: The Innovations of Niklas Arnberg
Introduction
Niklas Arnberg is a prominent inventor based in Umeå, Sweden. He has made significant contributions to the field of virology, particularly in the treatment of adenoviral infections. With a total of 2 patents, Arnberg's work focuses on innovative solutions to combat viral diseases.
Latest Patents
Arnberg's latest patents include "Multivalent sialic acid derivatives" and "Method and composition for the treatment of adenoviral ocular infections." The first patent discloses tri- or tetravalent sialic acid derivatives that inhibit the binding of adenovirus to human cells. This innovation has the potential to treat or prevent infections such as epidemic keratoconjunctivitis. The second patent addresses adenoviral infections, particularly ocular adenoviral infections like keratoconjunctivitis. It describes a method for treating these infections by administering a substance that interferes with the interaction between the virus and the sialic acid receptor.
Career Highlights
Niklas Arnberg is associated with Adenovir Pharma AB, a company dedicated to developing therapies for adenoviral infections. His work has been instrumental in advancing the understanding and treatment of these viral diseases.
Collaborations
Arnberg collaborates with notable colleagues, including Goran Wadell and Rémi Caraballo. Their combined expertise contributes to the innovative research and development efforts at Adenovir Pharma AB.
Conclusion
Niklas Arnberg's contributions to the field of virology through his patents and collaborations highlight his commitment to advancing medical science. His innovative approaches to treating adenoviral infections have the potential to make a significant impact on public health.